Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06985485) titled 'Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy' on May 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The First Affiliated Hospital of Soochow University
Condition:
Acute Lymphoblastic Leukemia
Immunotherapy
Blinatumomab
Inotuzumab Ozogamicin
Intervention:
Drug: Full-Course Immunotherapy
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: July 1, 2025
Target Sample Size: 30
Countries of Recruitment:
China
To...